Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors

News provided by

Dec 28, 2011, 05:43 ET

NEW YORK, Dec. 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors

http://www.reportlinker.com/p0284947/Triple-Analysis-Melanoma-Apoptosis-and-Protein-Kinase-Inhibitors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma

The melanoma report part comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 investigators, from Ceased to Marketed. This part extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

Part II: Apoptosis

The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.

This part is based on the following publication:

Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Protein Kinase Inhibitors

The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.

This part is based on the following publication:

Protein Kinase Therapeutics in Oncology - Where to Commercialize?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma

5.1 The Scope of this Report 25

6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (170 Drug Targets) 29-363

7 Emerging New Products to Established Ones: Drug Target Strategies of Melanoma Drugs by their Highest Stage of Development (151 Drug Target Strategies and 218 Melanoma Drugs) 364-538

8 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (8 Compound Strategies) 539-574

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Investigator (138 Companies) 575-766

10 Disclaimer 767

11 Drug Index 768

12 Company Index 773

Figures: Includes 6 Figures

Tables: Includes 196 Tables

Total Number of Pages: 777

Part II: Apoptosis

5.1 The Scope of this Report 33

6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416

7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622

8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660

9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601

Disclaimer 1602

11 Drug Index 1603

12 Company Index 1611

Figures: Includes 7 Figures

Tables: Includes 315 Tables

Total Number of Pages: 1,617

Part III: Protein Kinase Inhibitors

5.1 The Scope of this Report 30

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets) 36-336

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs) 337-407

8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound Strategies) 408-495

9 Selecting Cancer Indications for Protein Kinase Therapeutics (57 Different Cancer Indications) 496-649

10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator (160 Investigators) 650-1417

12 Drug Index 1419

13 Company Index 1433

Figures: Includes 6 Figures

Tables: Includes 302 Tables

Total Number of Pages: 1442

To order this report:

Drug and Medication Industry: Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors

More Market Research Report

Check our Industry Analysis and Insights